Our Strategy

Nitec has major competencies in the development and commercialization of innovative medicines for the treatment of chronic inflammatory and pain-related diseases, and is focused on building a strong product portfolio within these fields. The Company will also develop its pipeline through the selective acquisition of highly-promising novel compounds addressing major indications within its chosen fields.

At the same time, Nitec will out-license marketing rights to successful late stage compounds in certain countries. The Company will retain marketing rights on occasion in countries where it can market or co-promote the product effectively through a small specialized sales force.

In particular, Nitec’s strategy includes the following key elements:

• to launch Lodotra^™ for the treatment of rheumatoid arthritis (RA) in Europe once approval has been given,
• to complete a second pivotal phase 3 trial of Lodotra^™ in RA for US regulatory approval,
• to complete phase 2 trial for the treatment of severe asthma,
• to expand the Lodotra^™ label to include polymyalgia rheumatica,
• to advance the clinical development of TruNoc and
• to enter into additional development and commercialization partnerships to create a broad pipeline of therapeutics for chronic inflammation and pain-related diseases.